Form 4: COLL Director Sells Over 11,000 Shares

Collegium Pharmaceutical Director John Freund sold 11,659 shares of common stock for approximately $34.36 per share.

Summary

• John Freund, a Director and 10% Owner of Collegium Pharmaceutical, Inc. (COLL), sold 11,659 shares of common stock.
• The transaction occurred on August 8, 2025.
• The shares were sold at a weighted average price of $34.3632, with individual sales ranging from $34.27 to $34.535.
• Following the sale, Freund directly owns 70,658 shares and indirectly owns 23,129 shares through John Freund Family Partnership IV, L.P., and 8,625 shares through Skyline Venture Management V, LLC.

Sentiment

Score: 3

Explanation: The sale of shares by a director and 10% owner, especially a significant number, typically signals a negative sentiment or a belief that the stock is fully valued, which can be perceived as a bearish indicator by the market.

Negatives

• A director and 10% owner, John Freund, sold a significant number of shares (11,659 shares) of Collegium Pharmaceutical common stock.
• Insider selling can sometimes be interpreted as a lack of confidence in the company's near-term prospects or that the stock price has reached a peak.

Risks

• Potential negative market perception due to insider selling, which could lead to downward pressure on the stock price.

Industry Context

This transaction is an insider sale by a director in the pharmaceutical industry. While not indicative of broader industry trends, insider selling can sometimes reflect individual company-specific views rather than sector-wide shifts.

Related Party Transactions

• The shares indirectly held by John Freund Family Partnership IV, L.P. and Skyline Venture Management V, LLC are considered related party holdings, though the reported transaction is a direct sale by the reporting person.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

While insider selling can be a negative signal, this Form 4 only reports a single transaction by one director. Without additional context on the company's fundamentals, broader market conditions, or the director's personal financial planning, a 'hold' recommendation is prudent. Investors should monitor future insider activity and company performance before making a 'buy' or 'sell' decision.

Keywords

Collegium Pharmaceutical, COLL, Insider Sale, Form 4, Director Sale, Stock Transaction, John Freund, Pharmaceuticals